Myeloma Bone Disease: The Osteoblast in the Spotlight.
bone anabolic
multiple myeloma
myeloma bone disease
osteoblast
osteogenesis
osteolytic lesions
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
02 Sep 2021
02 Sep 2021
Historique:
received:
31
07
2021
revised:
24
08
2021
accepted:
27
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Lytic bone disease remains a life-altering complication of multiple myeloma, with up to 90% of sufferers experiencing skeletal events at some point in their cancer journey. This tumour-induced bone disease is driven by an upregulation of bone resorption (via increased osteoclast (OC) activity) and a downregulation of bone formation (via reduced osteoblast (OB) activity), leading to phenotypic osteolysis. Treatments are limited, and currently exclusively target OCs. Despite existing bone targeting therapies, patients successfully achieving remission from their cancer can still be left with chronic pain, poor mobility, and reduced quality of life as a result of bone disease. As such, the field is desperately in need of new and improved bone-modulating therapeutic agents. One such option is the use of bone anabolics, drugs that are gaining traction in the osteoporosis field following successful clinical trials. The prospect of using these therapies in relation to myeloma is an attractive option, as they aim to stimulate OBs, as opposed to existing therapeutics that do little to orchestrate new bone formation. The preclinical application of bone anabolics in myeloma mouse models has demonstrated positive outcomes for bone repair and fracture resistance. Here, we review the role of the OB in the pathophysiology of myeloma-induced bone disease and explore whether novel OB targeted therapies could improve outcomes for patients.
Identifiants
pubmed: 34501423
pii: jcm10173973
doi: 10.3390/jcm10173973
pmc: PMC8432062
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Cell Int. 2014 Dec 12;14(1):132
pubmed: 25520585
Am J Blood Res. 2014 Dec 15;4(2):73-85
pubmed: 25755907
Leukemia. 2003 Apr;17(4):764-74
pubmed: 12682635
Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9
pubmed: 20194748
Blood. 2011 Dec 22;118(26):6871-80
pubmed: 22042697
Cancer. 2007 Oct 15;110(8):1860-7
pubmed: 17763372
N Engl J Med. 2003 Dec 25;349(26):2483-94
pubmed: 14695408
Development. 2003 Sep;130(18):4295-305
pubmed: 12900447
Blood. 2005 Aug 15;106(4):1407-14
pubmed: 15878977
Br J Haematol. 2014 Jun;165(6):814-23
pubmed: 24650009
PLoS One. 2009;4(4):e5275
pubmed: 19357790
Semin Oncol. 2016 Dec;43(6):676-681
pubmed: 28061985
Mayo Clin Proc. 2003 Jan;78(1):21-33
pubmed: 12528874
Int J Cancer. 2006 Oct 1;119(7):1728-31
pubmed: 16646053
Leuk Lymphoma. 2002 Mar;43(3):635-9
pubmed: 12002771
Bone. 2016 Oct;91:81-91
pubmed: 27423464
Haematologica. 2006 Feb;91(2):192-9
pubmed: 16461303
Br J Haematol. 2014 Nov;167(3):366-75
pubmed: 25139740
J Biol Chem. 2015 Jul 3;290(27):16744-58
pubmed: 25953900
N Engl J Med. 2004 Jul 8;351(2):197-8
pubmed: 15247367
Blood. 1999 Dec 1;94(11):3883-8
pubmed: 10572104
Exp Cell Res. 2019 Oct 1;383(1):111490
pubmed: 31283912
Cancer Res. 2003 Jan 15;63(2):287-9
pubmed: 12543775
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193
pubmed: 29931216
Leukemia. 2019 Dec;33(12):2924-2933
pubmed: 31092894
Blood. 1997 Mar 1;89(5):1560-5
pubmed: 9057637
Blood. 2007 Mar 1;109(5):2106-11
pubmed: 17068150
Blood. 2001 Dec 15;98(13):3534-40
pubmed: 11739154
Br J Haematol. 2003 Jul;122(1):39-52
pubmed: 12823344
Mol Cancer Res. 2017 Apr;15(4):405-417
pubmed: 28119431
Bone. 2007 Sep;41(3):331-9
pubmed: 17613296
Cancer Res. 2020 Mar 1;80(5):1036-1048
pubmed: 31911552
Lancet Oncol. 2021 Mar;22(3):e119-e130
pubmed: 33545067
EMBO J. 2003 Dec 1;22(23):6267-76
pubmed: 14633986
Leukemia. 2011 Jul;25(7):1174-81
pubmed: 21403648
Biomedicines. 2019 Jan 05;7(1):
pubmed: 30621282
PLoS One. 2010 Mar 25;5(3):e9870
pubmed: 20360846
N Engl J Med. 2014 Jan 30;370(5):412-20
pubmed: 24382002
J Bone Miner Res. 2005 Mar;20(3):487-93
pubmed: 15746994
Blood. 2005 Oct 1;106(7):2472-83
pubmed: 15933061
Bone. 2011 Jan;48(1):129-34
pubmed: 20570621
Leuk Lymphoma. 2007 Dec;48(12):2323-9
pubmed: 18067006
J Bone Oncol. 2018 Sep 15;13:62-70
pubmed: 30591859
J Clin Invest. 2002 Dec;110(11):1643-50
pubmed: 12464669
Bone. 2013 Nov;57(1):10-7
pubmed: 23895995
J Hematol Oncol. 2018 May 18;11(1):67
pubmed: 29776381
Blood. 2015 Jun 4;125(23):3598-608
pubmed: 25862559
Leukemia. 2019 May;33(5):1063-1075
pubmed: 30770859
J Bone Miner Res. 2010 Dec;25(12):2633-46
pubmed: 20533325
Blood Rev. 2013 Nov;27(6):261-7
pubmed: 24054128
Blood. 2007 Apr 1;109(7):3024-30
pubmed: 17138824
J Bone Miner Res. 2014 Apr;29(4):935-43
pubmed: 23996473
Blood. 2002 Dec 15;100(13):4615-21
pubmed: 12393684
Haematologica. 2011 Nov;96(11):1653-61
pubmed: 21828122
Postgrad Med J. 2007 Apr;83(978):217-23
pubmed: 17403946
Bone. 1998 Aug;23(2):87-93
pubmed: 9701466
Blood Cancer J. 2016 Oct 7;6(10):e482
pubmed: 27716740
Ann N Y Acad Sci. 2010 Mar;1192:298-302
pubmed: 20392250
Blood. 1998 Feb 1;91(3):806-12
pubmed: 9446640
Blood. 2009 Jul 9;114(2):371-9
pubmed: 19417213
Nat Med. 2013 Feb;19(2):179-92
pubmed: 23389618
Br J Haematol. 2013 May;161(3):373-82
pubmed: 23431957
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
pubmed: 9520411
Bone. 2003 Jan;32(1):1-7
pubmed: 12584029
Lancet. 2017 Sep 30;390(10102):1585-1594
pubmed: 28755782
Blood Cancer J. 2014 Jun 13;4:e217
pubmed: 24927406
Nature. 2002 Jun 6;417(6889):664-7
pubmed: 12050670
J Bone Miner Res. 2009 Mar;24(3):425-36
pubmed: 19016584
Calcif Tissue Int. 2018 Feb;102(2):196-209
pubmed: 29098361
Clin Cancer Res. 2017 Jan 1;23(1):225-238
pubmed: 27440267
JBMR Plus. 2019 Mar 15;3(3):e10183
pubmed: 30918921
Blood. 2005 Nov 1;106(9):3160-5
pubmed: 16030194
Sci Signal. 2020 May 26;13(633):
pubmed: 32457115
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Blood. 2001 Oct 1;98(7):2269-71
pubmed: 11568016
Am J Pathol. 2016 Mar;186(3):678-90
pubmed: 26801735
Blood Cancer J. 2011 Jun;1(6):e27
pubmed: 22829171
Leukemia. 2013 Feb;27(2):451-63
pubmed: 22781592
Blood. 2017 Jun 29;129(26):3452-3464
pubmed: 28515094
Curr Opin Mol Ther. 2010 Oct;12(5):586-97
pubmed: 20886391
Cancer. 1997 Oct 15;80(8 Suppl):1588-94
pubmed: 9362426
Lancet Haematol. 2018 Feb;5(2):e63-e72
pubmed: 29331635
Int J Cancer. 2012 Sep 15;131(6):1466-71
pubmed: 22052418
Calcif Tissue Int. 1993 Nov;53(5):362-4
pubmed: 8287326
J Clin Invest. 2000 Dec;106(12):1481-8
pubmed: 11120755
Nat Commun. 2019 Oct 4;10(1):4533
pubmed: 31586071
Ann Oncol. 2012 Oct;23(10):2681-2686
pubmed: 22492699
Biochem Biophys Res Commun. 2007 May 18;356(4):1004-10
pubmed: 17397798
Oncotarget. 2014 Dec 30;5(24):12950-67
pubmed: 25460501
J Bone Miner Res. 2019 Dec;34(12):2311-2326
pubmed: 31442332
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7644-8
pubmed: 8755529
J Bone Miner Res. 2019 May;34(5):783-796
pubmed: 30320927
Clin Exp Metastasis. 2008;25(2):149-59
pubmed: 18027090
Microbiol Spectr. 2016 Jun;4(3):
pubmed: 27337470
J Investig Med. 2020 Jan;68(1):45-51
pubmed: 31784427
Blood Cancer J. 2018 Jan 12;8(1):7
pubmed: 29330358
Blood. 2008 Jul 1;112(1):196-207
pubmed: 18305214
Leukemia. 2015 Jan;29(1):207-17
pubmed: 24787487
Ann N Y Acad Sci. 2011 Nov;1237:19-23
pubmed: 22082361
Blood. 2004 Mar 15;103(6):2308-15
pubmed: 14615378
PLoS One. 2017 May 10;12(5):e0174884
pubmed: 28489849
Eur J Cancer Care (Engl). 2017 Nov;26(6):
pubmed: 28940410
Ann Clin Biochem. 2018 May;55(3):308-327
pubmed: 29368538
J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34
pubmed: 12775774
Br J Cancer. 2016 Oct 25;115(9):1147-1155
pubmed: 27727232
Leukemia. 2017 Dec;31(12):2652-2660
pubmed: 28479592
Gene. 2004 Oct 27;341:19-39
pubmed: 15474285
JAMA Oncol. 2018 Sep 1;4(9):1221-1227
pubmed: 29800065
Blood. 2012 Sep 27;120(13):2620-30
pubmed: 22517906
J Cell Biol. 2013 Feb 18;200(4):537-49
pubmed: 23401003
Semin Cancer Biol. 2010 Jun;20(3):186-95
pubmed: 20416379
Blood. 1996 Mar 1;87(5):1928-38
pubmed: 8634441
N Engl J Med. 2017 Oct 12;377(15):1417-1427
pubmed: 28892457